Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis

By sjmartinez • September 8, 2023

Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, Drakaki A, Rettig M, Czernin J, Calais J. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with ¹⁷⁷Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023 Sep 7:jnumed.122.265155. doi: 10.2967/jnumed.122.265155. Epub ahead of print. PMID: 37678927.

Tags: 177Lu-PSMA, Cardiology/Epi, end-of-treatment PET, Hematology/Oncology, metastatic castration-resistant prostate cancer, PSMA-PET, Publications, radioligand therapy

Barriers and Emerging Strategies to Bridge Gaps in Implementation of Evidence-Based Lipid-Lowering Therapies

Marnell CS, Koenig W, Bittner V, Watson KE, Muntner P, Nordestgaard BG, Yan LL, Verbakel M, Rosenson RS. Barriers and Emerging Strategies to Bridge Gaps[...]

New 10-Year Atherosclerosis Cardiovascular Disease Risk Score for Asian and American Indian Women Service Members

Jeon-Slaughter H, Whyne EZ, Doyle C, Chen X, Chiou SH, Tsai S, Ebrahimi R. New 10-Year Atherosclerosis Cardiovascular Disease Risk Score for Asian and American[...]

Cardiovascular disease mortality among women diagnosed with de novo metastatic breast cancer

Ramin C, Gresham G, Li J, Karlstaedt A, Hashibe M, Nikolova AP, Atkins KM. Cardiovascular disease mortality among women diagnosed with de novo metastatic breast[...]